Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYNIG5)

Drug Name

WS-070117 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hyperlipidaemia	5C80	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lipoprotein lipase (LPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[2]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[3]
AMT-011	DM8QIRN	Blood forming organ disorder	JB64.1	Phase 3	[1]
Ibrolipim	DMOPWSX	Hyperlipidaemia	5C80	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
2	Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95.
3	Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.
4	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92.